Abstract

FEACAL MICROBIOTA TRANSPLANTS IN CLOSTRIDIUM DIFFICILE INFECTION, INFLAMMATORY BOWEL DISEASE, OBESITY, METABOLIC SYNDROME

*K. Rishitha, L. Divya Bhargavi, P. Deepthi, Dr. G. Ramesh, Satheesh S. Gottipati and Dr. P. Srinivasa Babu

ABSTRACT

Fecal microbiota transplantation (FMT) has been shown to be more effective in treating relapsing or refractory Clostridium difficile infection (CDI) and, potentially, inflammatory bowel disease (IBD). In clinical setting, the FMT was noted to significantly lower the risk of recurrent CDI, likely by increasing microbial diversity and altering the metabolic environment in the intestinal tract of recipients. The efficacy of FMT in the treatment of IBD appears to be influenced by a number of factors, including donor microbial profiles, inflammatory burden, and the microbial diversity of the recipient. The administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s gut microbial composition and confer a health benefit is fecal microbiota transplantation (FMT). It may also carry therapeutic potential for other conditions such as inflammatory bowel disease, obesity, metabolic syndrome, and functional gastrointestinal disorders.

Keywords: Fecal bacteriotherapy, Clostridium difficile infection, Inflammatory bowel disease, gutmicrobiome, Probiotics.